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I’d like to introduce you to Scott Johnson, who thinks he has
a better way of translating basic research discoveries into
therapies for human diseases. Like many of the other people
who have made a difference in the battle to cure diseases
that pharmaceutical companies and governments have
largely ignored - for example, the actor Michael J Fox in the
case of Parkinson’s disease and the financier Michael Milken
in the case of prostate cancer - Mr Johnson has a very per-
sonal reason for wanting to see a particular disease cured. In
1976, when he was 20 years old, Scott Johnson was diag-
nosed with multiple sclerosis. He’s 50 now, and he knows
that, without a cure, his life expectancy is predicted to be
about 7 years less than the average for a healthy adult. But
that isn’t the main reason that Scott Johnson is a man in a
hurry. He’s in a hurry because he thinks he’s figured it out,
and when you think you’ve figured it out, you’re naturally
anxious to see if you’re right.
Based on his track record, it might be unwise to bet against
him. Multiple sclerosis didn’t prevent him from a successful
business career with the Boston Consulting Group and
several Silicon Valley startups. That wouldn’t make him the
first businessman who thought he could apply the principles
of corporate management to a new area (government is a
favorite one), not by any means. But Mr Johnson doesn’t
want to run a state, or even a city. He wants to change the
way cures for diseases are found.
In 2003 he left business to start the Myelin Repair Founda-
tion. The origins and progression of multiple sclerosis, which
is thought to be an autoimmune disease, are mysterious and
unpredictable, but the hallmark of the disease is the destruc-
tion of the myelin sheath that surrounds the axons of nerve
fibers of the central nervous system. The resulting scar tissue
(sclerosis) gives the disease its name. When Scott Johnson
heard about myelin, he decided that the fastest route to a
cure for multiple sclerosis was not to focus on the causes of
the disease but rather to find a way to repair the damaged
myelin. Hence the name of his foundation, and its goal.
Having decided that, the question then became how best to
get there. Johnson looked at existing models for what is now
often called translational research and decided that none of
them was very efficient. “In traditional medical research,
numerous individual scientists work in relative isolation,
often in competition, focused on their specific field of exper-
tise. With little or no collaboration, discoveries are trans-
ferred by publication, resulting in sequential investigations
and greatly expanding the length of time necessary for vali-
dation and translation to further drug development and clin-
ical trials,” he says. He came up with a different model.
The Myelin Repair Foundation set about finding a way to
accelerate the basic science necessary to achieve its goal of
licensing at least one myelin repair drug target by 2009 that
would lead to treatments for multiple sclerosis. To accom-
plish this, the Foundation developed what it calls the Accel-
erated Research Collaboration™ (ARC; the name is
trademarked, actually) model, a business-science hybrid
model for medical research that was designed to break down
what Johnson saw as the barriers inherent in the traditional
medical research model. He thought that, if he was right,
this new model might be able to drive new discoveries
toward clinical trials in record time.
Instead of the traditional single-investigator-driven model
typical in virtually all academic research, the ARC model
combines the efforts of multiple investigators into a collabo-
rative, outcome-focused effort. Johnson tried to identify a
set of top-flight basic research laboratories, some of which
were not initially working directly on multiple sclerosis, and
convinced them to get interested in both the disease and his
approach to tackling it. Selection was based on their comple-
mentary knowledge and expertise, and their past contribu-
tions to understanding the key biological processes and
interactions that control myelination. These were people
who would quite likely have been competitors in the tradi-
tional research model. Five labs were chosen, scattered all
over the US and Canada. To enable communication amongthem, the Foundation set up a web-enabled infrastructure
designed to facilitate daily interaction and data exchanges;
discoveries are therefore shared immediately, without the
delays associated with the publication of scientific papers. A
requirement of being part of the ARC scientific team is the
commitment to design experiments that are part of a larger
research plan focused on identifying therapeutic targets that
will lead to patient treatments. The model provides a frame-
work for establishing membership and technology transfer
agreements with each participating university. Patents are
filed on all discoveries that may contribute to potential treat-
ments.
The Foundation believes the ARC model can be applied to any
medical research problem once relevant basic scientific dis-
coveries have been made. It states that more than 40 different
disease research organizations have made contact with the
Myelin Repair Foundation to learn about the ARC model and
its potential application to each organization’s research; these
include the American Cancer Society, The Down Syndrome
Research and Treatment Foundation, the Juvenile Diabetes
Research Foundation and the Harvard Stem Cell Institute.
It’s important to get past the marketing language and the
PowerPoint slides showing in iconic form the revolutionary
new approach to doing science. Versions of what the Myelin
Repair Foundation is trying to do have existed for decades,
differing in details but not in aims or overall philosophy.
What is significant about the Foundation and its ARC model
is that it has attracted so much attention. What does that tell
us about the state of scientific research in the genomics era?
I think what it tells us is that the scientific community has
sold the public on enormous increases in support for basic
biomedical research by promising that such research would
lead to cures for diseases, and that the public is growing
impatient with the pace of that translation. Nowhere is this
more evident than in the various genomics programs: the
Human Genome Sequencing Project, the Structural Genomics
Initiative, the Haplotype Mapping Initiative - all these and
more have been funded because their proponents promised
that the results generated by these massive, expensive pro-
grams would lead to a new era in medical treatments. As, of
course, they will, but it’s reasonable to ask whether the
mechanisms for getting there are optimal. The excitement in
some quarters over the Myelin Repair Foundation model
suggests to me that government funding agencies have not
managed to find, or at least to implement, mechanisms that
encourage collaborations and that reward innovation and
risk-taking. More than ten years after the human genome
sequencing project began, it still takes, on average, more
than 12 years and almost a billion dollars to make a drug.
The Myelin Repair Foundation aims to license at least one
myelin repair drug target to a major pharmaceutical company
by 2009, five years after its inception. Given that much
target validation is done outside of the pharmaceutical
industry, it’s hard to know how much of an acceleration that
represents. The likelihood is that it will still take close to 12
more years before a drug reaches the market.
But consider the case of Gleevec, Novartis’s Bcr-Abl tyrosine
kinase inhibitor for chronic myelogenous leukemia. The
Philadelphia chromosomal rearrangement producing the
activated kinase was observed in leukemia patients in 1960.
The kinase itself was first identified as a possible cause of the
disease in 1985. It was shown to be a cause of leukemia in
mice in 1990. Gleevec was approved by the US Food and
Drug Administration in 2001. Depending on whether you
consider the story to have begun in 1960 or in 1985, it either
took 17 years or 32 years to proceed from first glimpse of the
target to the clinic. Seventeen years would be just about what
the Myelin Repair Foundation can expect if its model works,
maybe a bit faster if they’re lucky. That wouldn’t represent
much of an acceleration at all. But going from 32 to 17 years
would be a pretty big deal.
Genomics was supposed to produce a revolution in human
health. It will, of course, but I think it’s legitimate to ques-
tion whether our mechanisms for translating the results of
such research into real therapies aren’t also ripe for a revolu-
tion. The RoadMap Program of the National Institutes of
Health (NIH) has run into a lot of criticism; it is seen as an
attempt by the NIH Director, Dr Elias Zerhouni, to drive bio-
medical research away from basic science towards transla-
tional research. As far as I can tell, that isn’t what it’s about
at all. For one thing, it only consumes a very small portion of
the total NIH budget. For another, it was conceived as a
blueprint for how everything should be done; it was designed
to be a laboratory in which different research models and
different funding mechanisms could be tried out. I don’t
think that’s a bad idea at all, and I think the criticism of it is
based partly on its unfortunate name (‘Laboratory’ would be
so much better than ‘RoadMap’) and partly on the fear that
somehow it’s taking money out of our own research pockets.
Given the number of wasteful initiatives in other NIH Insti-
tutes and Centers, this is hardly a fair criticism. It’s also
totally inconsistent. I’ve heard many investigators claim,
with much justification, that government scientific funding
agencies are far too conservative. To go blithely from that
charge to a charge that the RoadMap is too radical strikes me
as bordering on silly.
Considering that our scientific enterprise is peopled largely
by trained experimentalists, it’s surprising that there is so
much resistance to trying out new things. Fear that the
experiment may fail would never be an acceptable reason for
not doing it on the part of one’s own graduate students or
postdocs. The ARC model that Scott Johnson is so excited
about may or may not represent a better way of doing certain
things, but at least he’s trying the experiment.
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